Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443058 | 0.81 | CYP2C9 (0.39) | CYP2C19CYP2C9TSHRMTORHRH4 | |
| SCHEMBL12714418 | 0.78 | CYP2C9 (0.32) | CYP2C19CYP2C9TSHRMTORHRH4 | |
| SCHEMBL18871348 | 0.77 | CYP2C9 (0.36) | CYP2C19CYP2C9TSHRMTORHRH4 | |
| SCHEMBL10249790 | 0.77 | CYP2C9 (0.34) | CYP2C19CYP2C9TSHRMTORHRH4 | |
| SCHEMBL12928753 | 0.75 | CYP2C9 (0.36) | CYP2C19CYP2C9TSHRMTORHRH4 | |
| SCHEMBL1045230 | 0.75 | CYP2C9 (0.36) | CYP2C19CYP2C9TSHRMTORHRH4 | |
| SCHEMBL2611129 | 0.74 | TSHR (0.39) | CYP2C19CYP2C9TSHRMTORHRH4 | |
| SCHEMBL25015250 | 0.74 | CYP2C9 (0.38) | CYP2C19CYP2C9TSHRMTORHRH4 | |
| SCHEMBL13944416 | 0.74 | CYP2C9 (0.38) | CYP2C19CYP2C9TSHRMTORHRH4 | |
| SCHEMBL24311782 | 0.74 | CYP2C9 (0.34) | CYP2C19CYP2C9TSHRMTORHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3889154-A1 | HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020135771-A1 | HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 武汉朗来科技发展有限公司 | 2020-07-02 | — | — | WO | disclosed |
| WO-2016177686-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-10 | — | — | WO | disclosed |
| US-9487504-B2 | Imidazolyl analogs as syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20150175575-A1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2015-06-25 | — | — | US | disclosed |
| WO-2008137609-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175575-A1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | SYK, BTK, LCK | CYP2C19 841/4885CYP2C9 1394/4885TSHR 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.